BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 28387662)

  • 1. Clinical significance of serum dynamics of HSP90a level in esophageal squamous cell carcinoma patients treated with definitive chemoradiotherapy.
    Yan H; Li B; Fan T; Jiang S; Wang R; Sun M
    Cancer Biomark; 2017; 19(2):185-192. PubMed ID: 28387662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytokeratin 19 fragment antigen 21-1 as an independent predictor for definitive chemoradiotherapy sensitivity in esophageal squamous cell carcinoma.
    Yan HJ; Wang RB; Zhu KL; Jiang SM; Zhao W; Xu XQ; Feng R
    Chin Med J (Engl); 2012 Apr; 125(8):1410-5. PubMed ID: 22613644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic impact of tumor IL-6 expression after preoperative chemoradiotherapy in patients with advanced esophageal squamous cell carcinoma.
    Yoneda M; Fujiwara H; Furutani A; Ikai A; Tada H; Shiozaki A; Komatsu S; Kubota T; Ichikawa D; Okamoto K; Konishi H; Murayama Y; Kuriu Y; Ikoma H; Nakanishi M; Ochiai T; Otsuji E
    Anticancer Res; 2013 Jun; 33(6):2699-705. PubMed ID: 23749929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ZNF750 Expression as a Novel Candidate Biomarker of Chemoradiosensitivity in Esophageal Squamous Cell Carcinoma.
    Otsuka R; Akutsu Y; Sakata H; Hanari N; Murakami K; Kano M; Takahashi M; Matsumoto Y; Sekino N; Yokoyama M; Iida K; Matsubara H
    Oncology; 2017; 93(3):197-203. PubMed ID: 28558382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of CYFRA21-1, CEA and hemoglobin in patients with esophageal squamous cancer undergoing concurrent chemoradiotherapy.
    Zhang HQ; Wang RB; Yan HJ; Zhao W; Zhu KL; Jiang SM; Hu XG; Yu JM
    Asian Pac J Cancer Prev; 2012; 13(1):199-203. PubMed ID: 22502668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined fibrinogen and neutrophil-lymphocyte ratio as a prognostic marker of advanced esophageal squamous cell carcinoma.
    Kijima T; Arigami T; Uchikado Y; Uenosono Y; Kita Y; Owaki T; Mori S; Kurahara H; Kijima Y; Okumura H; Maemura K; Ishigami S; Natsugoe S
    Cancer Sci; 2017 Feb; 108(2):193-199. PubMed ID: 27889946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutrophil-to-lymphocyte ratio as a prognostic biomarker for patients with locally advanced esophageal squamous cell carcinoma treated with definitive chemoradiotherapy.
    Zhou XL; Li YQ; Zhu WG; Yu CH; Song YQ; Wang WW; He DC; Tao GZ; Tong YS
    Sci Rep; 2017 Feb; 7():42581. PubMed ID: 28195186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TENERGY: multicenter phase II study of Atezolizumab monotherapy following definitive Chemoradiotherapy with 5-FU plus Cisplatin in patients with unresectable locally advanced esophageal squamous cell carcinoma.
    Bando H; Kotani D; Tsushima T; Hara H; Kadowaki S; Kato K; Chin K; Yamaguchi K; Kageyama SI; Hojo H; Nakamura M; Tachibana H; Wakabayashi M; Fukutani M; Togashi Y; Fuse N; Nishikawa H; Kojima T
    BMC Cancer; 2020 Apr; 20(1):336. PubMed ID: 32312286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The crucial role of blood VEGF kinetics in patients with locally advanced esophageal squamous cell carcinoma receiving curative concurrent chemoradiotherapy.
    Chen YH; Lu HI; Lo CM; Wang YM; Chou SY; Hsiao CC; Huang CC; Shih LH; Chen SW; Li SH
    BMC Cancer; 2018 Aug; 18(1):837. PubMed ID: 30126380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of surgical resection in complete responders on FDG-PET after chemoradiotherapy for locally advanced esophageal squamous cell carcinoma.
    Jeong Y; Kim JH; Kim SB; Yoon DH; Park SI; Kim YH; Kim HR; Jung HY; Lee GH; Ryu JS
    J Surg Oncol; 2014 Apr; 109(5):472-7. PubMed ID: 24301552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genome-wide and size-based cell-free DNA indices as predictive biomarkers for locally advanced esophageal squamous cell carcinoma treated with preoperative or definitive chemoradiotherapy.
    Kim EJ; Im HS; Lee J; Cho EH; Kim YH; Kim HR; Kim JH; Park SR
    Curr Probl Cancer; 2021 Jun; 45(3):100685. PubMed ID: 33342577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of definitive chemoradiotherapy and radiotherapy alone in patients older than 75 years with locally advanced esophageal carcinoma: A retrospective cohort study.
    Zhao Q; Hu G; Xiao W; Chen Y; Shen M; Tang Q; Ning X
    Medicine (Baltimore); 2017 Sep; 96(35):e7920. PubMed ID: 28858114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant chemotherapy may not benefit esophageal squamous cell carcinoma patients treated with definitive chemoradiotherapy.
    Chen MQ; Lin QL; Chen YG; Guo JH; Xu BH; Tian Y
    J Chin Med Assoc; 2017 Oct; 80(10):636-643. PubMed ID: 28716602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term outcomes of combined endoscopic resection and chemoradiotherapy for esophageal squamous cell carcinoma with submucosal invasion.
    Yoshimizu S; Yoshio T; Ishiyama A; Tsuchida T; Horiuchi Y; Omae M; Hirasawa T; Asari T; Chin K; Fujisaki J
    Dig Liver Dis; 2018 Aug; 50(8):833-838. PubMed ID: 29477349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High serum levels of vascular endothelial growth factor-A and transforming growth factor-β1 before neoadjuvant chemoradiotherapy predict poor outcomes in patients with esophageal squamous cell carcinoma receiving combined modality therapy.
    Cheng JC; Graber MS; Hsu FM; Tsai CL; Castaneda L; Lee JM; Chang DT; Koong AC
    Ann Surg Oncol; 2014 Jul; 21(7):2361-8. PubMed ID: 24623035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum soluble E-cadherin is a potential prognostic marker in esophageal squamous cell carcinoma.
    Chung Y; Law S; Kwong DL; Luk JM
    Dis Esophagus; 2011 Jan; 24(1):49-55. PubMed ID: 20807231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pre- versus postoperative chemoradiotherapy for locally advanced esophageal squamous cell carcinoma.
    Hsu PK; Chen HS; Liu CC; Huang CS; Hsieh CC; Hsu HS; Wu SC
    J Thorac Cardiovasc Surg; 2017 Aug; 154(2):732-740.e2. PubMed ID: 28457536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic factors in clinical T1N0M0 thoracic esophageal squamous cell carcinoma invading the muscularis mucosa or submucosa.
    Uchinami Y; Myojin M; Takahashi H; Harada K; Shimizu S; Hosokawa M
    Radiat Oncol; 2016 Jun; 11():84. PubMed ID: 27328734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unexpected Microscopically Positive Proximal Resection Margins in Esophageal Squamous Cell Carcinoma After Chemoradiotherapy: Predictors and Prognostic Significance.
    Chiu CH; Chao YK; Wen YW; Chang HK; Tseng CK; Liu YH
    World J Surg; 2017 Jan; 41(1):191-199. PubMed ID: 27730349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A six-CpG panel with DNA methylation biomarkers predicting treatment response of chemoradiation in esophageal squamous cell carcinoma.
    Chang WL; Lai WW; Kuo IY; Lin CY; Lu PJ; Sheu BS; Wang YC
    J Gastroenterol; 2017 Jun; 52(6):705-714. PubMed ID: 27671002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.